Proteogenomic analysis refines medulloblastoma into seven molecular subtypes, revealing new therapeutic targets
核心洞察
A Kookmin University-led team integrated genomic, transcriptomic, epigenomic, proteomic, and phosphoproteomic data from over 100 medulloblastoma (搜索) patients to refine the conventional four molecular groups into seven distinct subtypes.
The SHHβ and G4γ subtypes showed enhanced neuronal differentiation and relatively favorable outcomes, while SHHα, G4α, and G4β were linked to higher risk of recurrence and progression.
Researchers identified subtype-specific protein signaling pathways and potential therapeutic targets, laying groundwork for precision medicine-based targeted therapies.
A research team at Kookmin University has identified previously unrecognized molecular subtypes of medulloblastoma (搜索), the most common malignant brain tumor in children, opening new possibilities for personalized treatment. The study, led by applied chemistry professor Kim Kyung-hee, was conducted as part of the National Cancer Center's Cancer Proteogenomics Research Program, an initiative dedicated to advancing proteogenomics-based precision medicine for cancer.
The collaborative effort brought together researchers from multiple Korean institutions, including Kim Young-wook of the National Cancer Center, Park Jong-bae of Kyung Hee University, Kim Seung-ki of Seoul National University, Yoon Jong-hyuck of the Korea Brain Research Institute, and Jason K. Sa of Korea University. International collaborators included Antonio Iavarone and Fulvio D'Angelo from the University of Miami Miller School of Medicine and Michael D. Taylor of the Toronto-based Hospital for Sick Children.
Refining the molecular classification of medulloblastoma
The researchers performed a comprehensive proteogenomic analysis by integrating genomic, transcriptomic, epigenomic (DNA methylome), proteomic, and phosphoproteomic data from tumor samples collected from more than 100 patients with medulloblastoma (搜索). Based on this integrated analysis, the team refined the conventional four molecular groups of medulloblastoma — WNT, SHH, Group 3, and Group 4 — into seven distinct molecular subtypes.
Specifically, the researchers subdivided the SHH group into SHHα and SHHβ, and Group 4 into G4α, G4β, and G4γ. The study found that this refined classification more accurately captures the biological characteristics of the tumors and predicts their clinical outcomes.
Clinical implications of the new subtypes
The analysis revealed meaningful differences in prognosis across the newly defined subtypes. The SHHβ and G4γ subtypes exhibited enhanced neuronal differentiation and were associated with relatively favorable clinical outcomes. In contrast, the SHHα, G4α, and G4β subtypes were linked to a higher risk of disease recurrence and progression.
Beyond refining the classification, the researchers identified subtype-specific protein signaling pathways and uncovered potential therapeutic targets for each molecular subtype, highlighting new opportunities for precision medicine-based targeted therapies.
Addressing an unmet clinical need
Medulloblastoma (搜索) is the most common malignant brain tumor in children, and the current standard of care consists of surgical resection followed by radiation therapy and chemotherapy. However, substantial molecular heterogeneity among patients results in marked differences in treatment response and clinical outcomes. Survival rates following tumor recurrence remain poor, underscoring the need for precision medicine approaches based on the molecular characteristics of individual tumors.
"Our integrated analysis of cancer proteogenomic data, which captures the functional characteristics of tumors, has enabled us to develop a more refined classification system that provides a deeper understanding of the molecular diversity of medulloblastoma (搜索)," said professor Kim of Kookmin University. She added, "We expect these findings to serve as an important foundation for developing personalized treatment strategies and subtype-specific targeted therapies in the future."
The findings were published in the peer-reviewed medical journal Experimental & Molecular Medicine under the title "Comprehensive proteogenomic characterization reveals clinically relevant molecular subtypes associated with medulloblastoma (搜索) progression."